U.S. drug tariffs may be waived for generic drugs, including common medications such as antibiotics, which account for 90% of Americans' daily medication usage.
```
The Trump administration said it does not plan to impose tariffs on foreign generic drugs. This decision involves imported generic drugs that make up 90% of Americans’ daily medication consumption.
On October 8, spokespeople from both the White House and the U.S. Department of Commerce confirmed that the government is not actively discussing imposing tariffs on generic drugs under the “Section 232” national security investigation framework.
This potential exemption is significant, as it would affect about 90% of all prescription drugs taken by Americans, including antibiotics, heart medications, and other daily medicines that rely heavily on imports. Officials supporting the exemption had previously expressed concern that tariffs on generic drugs would cause consumers to face rising prices or even drug shortages.
Although the likelihood of tariffs on generics has decreased, the Trump administration has not abandoned its goal of “manufacturing reshoring.” According to reports, the U.S. government is considering whether to issue an executive order to provide federal funding or loans to domestic manufacturers of key generic drugs.
This may involve using funds from foreign governments such as Japan, which are part of tariff agreements with the Trump administration, even though such infrastructure funding has yet to be established.
Scope of Tariffs Narrowed Significantly
Excluding generic drugs from the tariff list marks a significant narrowing in the scope of the U.S. Department of Commerce’s “Section 232” investigation into pharmaceutical products.
Last month, Trump announced online that on October 1 tariffs of 100% would be imposed on branded drugs but made no mention of generics.
As early as this April, the U.S. government had issued a notice stating it would use Section 232 of the 1962 Trade Expansion Act to investigate “finished generic drugs and non-generic drug products” as well as pharmaceutical ingredients.
This move not to plan tariffs on foreign generics is also a reversal from Trump’s campaign promises. In a 2023 campaign video, Trump said:
He would phase in tariffs and import restrictions to bring back all essential drug production to the U.S., including many common generics.
However, the latest policy direction suggests that the U.S. government is now taking a more cautious approach to using tariffs as a tool to reshape the pharmaceutical supply chain.
Clear Divisions Within the Administration
According to reports quoting informed sources, there are clear divisions within the administration over tariffs on generics.
Some officials, represented by Trump Domestic Policy Council member Theo Merkel, warned that imposing tariffs on generic drugs would directly cause consumer costs to rise and could even trigger drug shortages.
They believe that, with countries like India having extremely low production costs—and nearly half of U.S. generics coming from India—even high tariffs may not make domestic production in the U.S. profitable.
On the other hand, some Commerce Department officials and protectionists close to Trump hold the opposite view.
They advocate that dependence on foreign generic producers is a national security risk, and that high tariffs combined with government support for new manufacturing facilities could make domestic production of generics profitable.
In addition, to prevent repeats of global supply chain disruptions seen during the pandemic, tariffs and quotas on generics may ultimately be necessary. U.S. Trade Representative Jamieson Greer stated:
The U.S. government is implementing a nuanced, multi-faceted approach to reposition generic drug manufacturing, ensuring Americans do not again suffer due to foreign dependence as during the COVID-19 era.
Florida Republican Senator Rick Scott last week wrote to government officials urging them to expand tariffs to include generics. Despite differences, White House spokesperson Kush Desai insisted:
There is no disagreement or difference of opinion between the White House and the Department of Commerce on this issue.
Risk DisclaimerThe market involves risks, and investment should be approached cautiously. This article does not constitute personal investment advice, nor does it consider the special investment objectives, financial situation, or needs of any particular user. Users should consider whether any opinions, views, or conclusions expressed herein are suitable for their specific circumstances. Any investment made accordingly is at their own risk. ```